

MYRIAD GENETICS INC
Form 8-K
April 01, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 1, 2014

MYRIAD GENETICS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction

of incorporation)

0-26642
(Commission

File Number)
320 Wakara Way

87-0494517
(IRS Employer

Identification No.)

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (801) 584-3600

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01 Regulation FD Disclosure.

On April 1, 2014, the Centers for Medicare & Medicaid Services (CMS) provided new, updated pricing for the sequencing of the BRCA1 and BRCA2 genes. The new pricing resulted in a total reimbursement amount for Myriad's integrated BRCA^{Analysis}® of \$2,767. Below is a summary of the change in pricing for the relevant codes:

Description and CPT Code	Previous FY14 CMS Pricing	New FY14 CMS Pricing	Percent Change
BRCA 1&2 seq & com dup/del (81211) BRCA^{Analysis}	\$1,438	\$2,184	52%
BRCA 1&2 uncom dup/del var (81213) BART®	\$583	\$583	No Change
Integrated BRCA^{Analysis}	\$2,021	\$2,767	37%

The new reimbursement amounts will take effect for tests ordered on or after April 1, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYRIAD GENETICS, INC.

Date: April 1, 2014

By: /s/ Peter D. Meldrum
Peter D. Meldrum
President and Chief Executive Officer

Page 3 of 3 pages